BUSINESS COMBINATIONS (Tables)

6 Months Ended

Mar. 31, 2022

Business Acquisition [Line Items]

Schedule of unaudited pro forma information

	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	March 31, 2022		March 31, 2021		March 31, 2022		March 31, 2021
Total revenues	$	143,023	$	109,088	$	268,337	$	217,125
Net income (loss)		(72,023)		(24)		(98,548)		(23,242)

HistoTox Labs

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Allocation as of
	March 31, 2022
Assets acquired and liabilities assumed:
Accounts receivable		977
Unbilled revenues		337
Operating lease ROU asset		2,239
Property and equipment		3,929
Intangible assets		8,300
Goodwill		9,339
Accounts payable		(150)
Accrued expenses		(136)
Customer advances		(207)
Operating lease liability		(2,239)
	$	22,389

Bolder BioPATH

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Allocation as of
	March 31, 2022
Assets acquired and liabilities assumed:
Accounts receivable		2,146
Unbilled revenues		1,798
Operating lease ROU asset		2,750
Property and equipment		6,523
Intangible asset		12,700
Other assets		34
Goodwill		36,206
Accounts payable		(153)
Accrued expenses		(243)
Deferred revenue		(662)
Deferred tax liability		(4,867)
Operating lease liability		(2,750)
	$	53,482

Gateway Pharmacology Laboratories LLC

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Preliminary
	Allocation as of
	March 31, 2022
Assets acquired and liabilities assumed:
Accounts receivable		422
Operating lease ROU asset		120
Property and equipment		359
Intangible asset		100
Other assets		9
Goodwill		2,207
Accounts payable		(54)
Accrued expenses		(72)
Deferred tax liability		(118)
Operating lease liability		(120)
	$	2,853

BioReliance Corporation

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Preliminary
	Allocation as of
	March 31, 2022
Assets acquired and liabilities assumed:
Property and equipment		175
Intangible asset		640
	$	815

Plato BioPharma Inc

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Preliminary
	Allocation as of
	March 31, 2022
Assets acquired and liabilities assumed:
Cash		1,027
Accounts receivable		860
Property and equipment		1,148
Operating lease ROU asset		2,582
Intangible asset		5,100
Goodwill		8,880
Operating lease liability		(2,566)
Other liabilities, net		(242)
Deferred tax liability		(1,551)
	$	15,238

Envigo RMS Holding Corp

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Preliminary
	Allocation as of
	March 31, 2022
Assets acquired and liabilities assumed:
Cash		3,091
Restricted cash		435
Trade receivables and contract assets		44,240
Inventory		39,138
Prepaid expenses and other current assets		18,960
Operating lease ROU assets, net		7,570
Property and equipment		83,608
Other assets		7,676
Intangible asset		201,000
Goodwill		356,947
Accounts payable		(17,298)
Fees invoiced in advance		(7,040)
Current portion of long-term operating lease		(2,729)
Accrued expenses and other liabilities		(22,382)
Long-term operating leases, net		(4,631)
Other liabilities		(3,834)
Long-term debt		(140)
Long-term deferred tax liabilities		(31,148)
Noncontrolling interest		1,111
	$	674,574

Schedule of information related to measurement assumptions

Stock price	53.31
Strike price	9.93
Volatility	75.93%
Expected term	3.05
Risk-free rate	0.62%

Robinson Services, Inc.

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Preliminary
	Allocation as of
	March 31, 2022
Assets acquired and liabilities assumed:
Customer relationship		4,700
Non-compete agreement		300
Supply agreement		200
Goodwill		948
	$	6,148

Integrated Laboratory Systems, LLC (ILS)

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Preliminary
	Allocation as of
	March 31, 2022
Assets acquired and liabilities assumed:
Cash		797
Trade receivables and contract assets		3,841
Prepaid expenses and other current assets		61
Property and equipment		2,237
Intangible asset		27,000
Goodwill		23,206
Accounts payable		(1,039)
Fees invoiced in advance		(1,696)
Accrued expenses and other liabilities		(1,136)
	$	53,271

Orient BioResource Center, Inc

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Preliminary
	Allocation as of
	March 31, 2022
Assets acquired and liabilities assumed:
Cash		5,481
Trade receivables and contract assets		2,025
Inventory		8,800
Prepaid expenses and other current assets		2,609
Property and equipment		8,790
Intangible asset		21,700
Goodwill		14,530
Accounts payable		(476)
Fees invoiced in advance		(6,548)
Accrued expenses and other liabilities		(354)
Long-term deferred tax liabilities		(5,649)
	$	50,908